Free Trial
OTCMKTS:FSNUY

Fresenius SE & Co. 7/31/2024 Earnings Report

Fresenius SE & Co. logo
$12.36 +0.10 (+0.82%)
As of 08/7/2025 03:58 PM Eastern

Fresenius SE & Co. EPS Results

Actual EPS
$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$5.83 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

Q2 2025 Fresenius SE & Co KGaA Earnings Call Transcript
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
Fresenius raises 2025 revenue guidance
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

View Fresenius SE & Co. Profile

More Earnings Resources from MarketBeat